RU2016107436A3 - - Google Patents

Download PDF

Info

Publication number
RU2016107436A3
RU2016107436A3 RU2016107436A RU2016107436A RU2016107436A3 RU 2016107436 A3 RU2016107436 A3 RU 2016107436A3 RU 2016107436 A RU2016107436 A RU 2016107436A RU 2016107436 A RU2016107436 A RU 2016107436A RU 2016107436 A3 RU2016107436 A3 RU 2016107436A3
Authority
RU
Russia
Application number
RU2016107436A
Other languages
Russian (ru)
Other versions
RU2016107436A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016107436A publication Critical patent/RU2016107436A/ru
Publication of RU2016107436A3 publication Critical patent/RU2016107436A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
RU2016107436A 2013-08-14 2014-08-14 Линейные пептидные антибиотики RU2016107436A (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361865980P 2013-08-14 2013-08-14
US201361865982P 2013-08-14 2013-08-14
US201361865986P 2013-08-14 2013-08-14
US61/865,986 2013-08-14
US61/865,982 2013-08-14
US61/865,980 2013-08-14
PCT/US2014/051151 WO2015023898A1 (en) 2013-08-14 2014-08-14 Linear peptide antibiotcs

Publications (2)

Publication Number Publication Date
RU2016107436A RU2016107436A (ru) 2017-09-19
RU2016107436A3 true RU2016107436A3 (enExample) 2018-05-22

Family

ID=52468711

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016107436A RU2016107436A (ru) 2013-08-14 2014-08-14 Линейные пептидные антибиотики

Country Status (9)

Country Link
US (1) US20160194358A1 (enExample)
EP (1) EP3033352A4 (enExample)
JP (1) JP2016528257A (enExample)
KR (1) KR20160044512A (enExample)
CN (1) CN105636978A (enExample)
CA (1) CA2921082A1 (enExample)
MX (1) MX2016001927A (enExample)
RU (1) RU2016107436A (enExample)
WO (1) WO2015023898A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
RU2698328C1 (ru) * 2019-02-27 2019-08-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Серебряные соли 5,6-диарил-4-[4-(ацетиламиносульфонил)фенил]-3,5-дигидропирроло[3,4-с]пиразол-3-онов, проявляющие противомикробную активность
CN111978371B (zh) * 2019-05-22 2022-05-13 成都诺和晟泰生物科技有限公司 一种多肽类衍生物及其在医药领域的用途
US20220289698A1 (en) * 2019-07-30 2022-09-15 Karl-Franzens-Universität Graz Inhibitors of human atgl
CN110606825A (zh) * 2019-10-30 2019-12-24 成都海杰亚医药科技有限公司 一种制备吡啶-2-硫醇的方法
CN110790817A (zh) * 2019-11-12 2020-02-14 成都诺和晟泰生物科技有限公司 一种多肽类化合物、制剂、药物组合物及制备方法、应用
EP4284804A1 (en) 2021-01-26 2023-12-06 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
CN116444378A (zh) * 2023-02-14 2023-07-18 广东优康精细化工有限公司 一种n-甲基异丙基胺的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136498A1 (en) * 1996-10-18 2001-09-26 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease
NZ335276A (en) * 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
CN103159830B (zh) * 2011-12-15 2017-06-20 上海来益生物药物研究开发中心有限责任公司 脂肽类化合物
KR20140132367A (ko) * 2012-02-16 2014-11-17 알큐엑스 파마슈티컬스, 인크. 선형 펩티드 항생제

Also Published As

Publication number Publication date
US20160194358A1 (en) 2016-07-07
MX2016001927A (es) 2016-09-08
WO2015023898A1 (en) 2015-02-19
CA2921082A1 (en) 2015-02-19
RU2016107436A (ru) 2017-09-19
EP3033352A4 (en) 2017-04-19
JP2016528257A (ja) 2016-09-15
CN105636978A (zh) 2016-06-01
KR20160044512A (ko) 2016-04-25
EP3033352A1 (en) 2016-06-22
WO2015023898A8 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
AP2016009275A0 (enExample)
BR112015007533A2 (enExample)
BR112016001627A2 (enExample)
BR112014017733A2 (enExample)
BR112014017739A2 (enExample)
BR112014019326A2 (enExample)
BR112014018502A2 (enExample)
BR112014018516A2 (enExample)
BR112014017765A2 (enExample)
BR112014018480A2 (enExample)
BR112014017855A2 (enExample)
BR112014020341A2 (enExample)
BR112015029139A2 (enExample)
BR112014018468A2 (enExample)
BR112015023235A2 (enExample)
BR112014018207A2 (enExample)
BR112014019204A2 (enExample)
BR112016009263A2 (enExample)
BR112014017901A2 (enExample)
BR112014017745A2 (enExample)
BR112014018483A2 (enExample)
BR112014017722A2 (enExample)
BR112014017653A2 (enExample)
BR112014017601A2 (enExample)
BR112015015312A2 (enExample)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190325